Sanofi disclosed on Thursday that they have entered into a deal with biopharmaceutical company Dren Bio to purchase their autoimmune disease treatment, DR-0201. Sanofi will buy Dren Bio's division, Dren-0201, for an initial payment of $600 million and potential additional payments amounting to $1.3 billion. The acquisition is anticipated to be finalized in the second quarter of 2025.